Tafamidis meglumine | CAS#951395-08-7 | Transthyretin Protein Stabilizer

MedKoo Cat#: 330120 | Name: Tafamidis meglumine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tafamidis, also known as Fx-1006 or PF-06291826, is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein.

Chemical Structure

Tafamidis meglumine

CAS#951395-08-7 (meglumine)

Theoretical Analysis

MedKoo Cat#: 330120

Name: Tafamidis meglumine

CAS#: 951395-08-7 (meglumine)

Chemical Formula: C21H24Cl2N2O8

Exact Mass: 0.0000

Molecular Weight: 503.33

Elemental Analysis: C, 50.11; H, 4.81; Cl, 14.09; N, 5.57; O, 25.43

Price and Availability

Size	Price	Availability
50mg	USD 250.00	2 Weeks
100mg	USD 450.00	2 Weeks
200mg	USD 750.00	2 Weeks
500mg	USD 1,350.00	2 Weeks
1g	USD 2,350.00	2 Weeks
2g	USD 3,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

594839-88-0 (free acid) 951395-08-7 (meglumine)

Synonym

Tafamidis meglumine; Fx 1006A; Fx-1006A; Fx1006A; PF-06291826; PF 06291826; PF06291826;

IUPAC/Chemical Name

(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid

InChi Key

DQJDBUPLRMRBAB-WZTVWXICSA-N

InChi Code

InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

SMILES Code

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC.O=C(C1=CC=C2N=C(C3=CC(Cl)=CC(Cl)=C3)OC2=C1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 503.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011 Dec;10(12):1086-97. doi: 10.1016/S1474-4422(11)70246-0. PMID: 22094129. 2: Hund E. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis. Appl Clin Genet. 2012 Jun 18;5:37-41. doi: 10.2147/TACG.S19903. PMID: 23776379; PMCID: PMC3681191. 3: Institute for Quality and Efficiency in Health Care. Tafamidis Meglumine -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2012 Mar 13. Extract of Dossier Assessment No. A11-31. PMID: 27905733. 4: Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629-34. doi: 10.1073/pnas.1121005109. Epub 2012 May 29. PMID: 22645360; PMCID: PMC3386102. 5: de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today (Barc). 2012 May;48(5):331-7. doi: 10.1358/dot.2012.48.5.1808486. PMID: 22645721. 6: Nencetti S, Rossello A, Orlandini E. Tafamidis (Vyndaqel): a light for FAP patients. ChemMedChem. 2013 Oct;8(10):1617-9. doi: 10.1002/cmdc.201300245. Epub 2013 Sep 2. PMID: 24000164. 7: Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec;6(6):1011-20. doi: 10.1007/s12265-013-9512-x. Epub 2013 Oct 8. PMID: 24101373; PMCID: PMC3838581. 8: Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. PMID: 26894299; PMCID: PMC4919130. 9: Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y, Morita H, Machii K, Ohta M, Takata A, Ikeda S. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. J Neurol Sci. 2016 Mar 15;362:266-71. doi: 10.1016/j.jns.2016.01.046. Epub 2016 Jan 22. PMID: 26944161. 10: Russo M, Vita GL, Stancanelli C, Mazzeo A, Vita G, Messina S. Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscul Disord. 2016 Jun;26(6):374-7. doi: 10.1016/j.nmd.2016.03.006. Epub 2016 Mar 30. PMID: 27132122. 11: Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016 Sep;23(3):178-183. doi: 10.1080/13506129.2016.1207163. Epub 2016 Aug 5. PMID: 27494299; PMCID: PMC5359776. 12: Fujita T, Inomata T, Kaida T, Iida Y, Ikeda Y, Nabeta T, Ishii S, Maekawa E, Naruke T, Koitabashi T, Kitamura E, Sekijima Y, Ako J. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report. Cardiology. 2017;137(2):74-77. doi: 10.1159/000455089. Epub 2017 Feb 3. PMID: 28152524. 13: Martens B, De Pauw M, De Bleecker JL. Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review. Acta Neurol Belg. 2018 Jun;118(2):179-185. doi: 10.1007/s13760-018-0906-z. Epub 2018 Mar 9. PMID: 29524093. 14: Salvi F, Volpe R, Pastorelli F, Bianchi A, Vella A, Rapezzi C, Mascalchi M. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis. J Stroke Cerebrovasc Dis. 2018 Sep;27(9):e212-e214. doi: 10.1016/j.jstrokecerebrovasdis.2018.04.033. Epub 2018 May 18. PMID: 29779881. 15: Monteiro C, Martins da Silva A, Ferreira N, Mesgarzadeh J, Novais M, Coelho T, Kelly JW. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018 Jun;25(2):120-128. doi: 10.1080/13506129.2018.1479249. Epub 2018 Jul 11. PMID: 29993288; PMCID: PMC6177313. 16: Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibashi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2019 Feb;6(1):232-236. doi: 10.1002/ehf2.12382. Epub 2018 Nov 27. PMID: 30478886; PMCID: PMC6352892. 17: Ishii T, Sekijima Y, Ando Y. Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan - interim analysis in post-marketing surveillance. Amyloid. 2019;26(sup1):45-46. doi: 10.1080/13506129.2019.1582508. PMID: 31343289. 18: Paton DM. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy. Drugs Today (Barc). 2019 Dec;55(12):727-734. doi: 10.1358/dot.2019.55.12.3078389. PMID: 31942875. 19: CADTH Canadian Drug Expert Committee Recommendation: Tafamidis Meglumine (Vyndaqel – Pfizer Canada ULC): Indication: For the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Feb 21. PMID: 33108144. 20: Lockwood PA, Le VH, O'Gorman MT, Patterson TA, Sultan MB, Tankisheva E, Wang Q, Riley S. The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers. Clin Pharmacol Drug Dev. 2020 Oct;9(7):849-854. doi: 10.1002/cpdd.789. Epub 2020 Mar 20. PMID: 32196976; PMCID: PMC7754314.